Thiotepa-based high-dose chemotherapy with autologous stem cell transplantation for neurolymphomatosis
Neurolymphomatosis (NL) is a rare clinical entity characterized by lymphomatous infiltration of the peripheral nervous system. According to recent retrospective data, consolidative high-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) may be beneficial for NL. However, few re...
Gespeichert in:
| Veröffentlicht in: | International journal of hematology 2023-07, Vol.118 (1), p.141-145 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 145 |
|---|---|
| container_issue | 1 |
| container_start_page | 141 |
| container_title | International journal of hematology |
| container_volume | 118 |
| creator | Miyajima, Toru Ogasawara, Reiki Tsukamoto, Shihori Ishio, Takashi Yokoyama, Emi Izumiyama, Koh Mori, Akio Saito, Makoto Morioka, Masanobu Kondo, Takeshi |
| description | Neurolymphomatosis (NL) is a rare clinical entity characterized by lymphomatous infiltration of the peripheral nervous system. According to recent retrospective data, consolidative high-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) may be beneficial for NL. However, few reports to date have discussed optimal conditioning regimens. Herein, we report two cases of NL in patients with relapsed intravascular large B-cell lymphoma who received consolidative thiotepa-containing HDC-ASCT. Case 1: A 56-year-old woman who relapsed 2 months after the first complete remission (CR) and underwent ASCT. Case 2: A 65-year-old woman who relapsed 8 months after the first CR and underwent ASCT. Both patients engrafted. Time to neutrophil engraftment was 10 and 12 days after HDC-ASCT, and CR was sustained for 26 and 18 months, respectively, as of the last follow-up. Although there is little evidence supporting the utility of thiotepa-based HDC-ASCT in patients with NL, the results of this case report suggest that further studies are warranted to determine its efficacy in this setting. |
| doi_str_mv | 10.1007/s12185-023-03544-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2768812286</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2768812286</sourcerecordid><originalsourceid>FETCH-LOGICAL-c350t-47c267412f7248af74766ccb03a07296c2b4e1db266c017437ccb9df1ba7b2673</originalsourceid><addsrcrecordid>eNp9kU9L5TAUxYMo-kb9Ai4k4MZNNP-amy5FZpwBwY2uQ9qmr5W2qUmKvG9vnk9HcOEqcO_vnpx7D0JnjF4xSuE6Ms50QSgXhIpCSqL30IppVRABIPfRipa8IAUweoR-xfhMKQMq4RAdCaV0SZVcofax631ysyWVja7BXb_uSOOjw3XnRp86F-y8wa996rBdkh_82i8Rx-RGXLthwCnYKc6DnZJNvZ9w6wOe3BL8sBnnzo82-djHE3TQ2iG604_3GD39-f14-5fcP9z9u725J7UoaCISaq5AMt4Cl9q2IEGpuq6osBR4qWpeSceaiudqXkYKyM2yaVllIRdBHKPLne4c_MviYjJjH7c-7eSyb8NBac041yqjF9_QZ7-EKbszPB9HiBL4VpDvqDr4GINrzRz60YaNYdRsUzC7FExOwbynYHQeOv-QXqrRNf9HPs-eAbEDYm5Naxe-_v5B9g2v25Pg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2890339727</pqid></control><display><type>article</type><title>Thiotepa-based high-dose chemotherapy with autologous stem cell transplantation for neurolymphomatosis</title><source>Springer Nature - Complete Springer Journals</source><creator>Miyajima, Toru ; Ogasawara, Reiki ; Tsukamoto, Shihori ; Ishio, Takashi ; Yokoyama, Emi ; Izumiyama, Koh ; Mori, Akio ; Saito, Makoto ; Morioka, Masanobu ; Kondo, Takeshi</creator><creatorcontrib>Miyajima, Toru ; Ogasawara, Reiki ; Tsukamoto, Shihori ; Ishio, Takashi ; Yokoyama, Emi ; Izumiyama, Koh ; Mori, Akio ; Saito, Makoto ; Morioka, Masanobu ; Kondo, Takeshi</creatorcontrib><description>Neurolymphomatosis (NL) is a rare clinical entity characterized by lymphomatous infiltration of the peripheral nervous system. According to recent retrospective data, consolidative high-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) may be beneficial for NL. However, few reports to date have discussed optimal conditioning regimens. Herein, we report two cases of NL in patients with relapsed intravascular large B-cell lymphoma who received consolidative thiotepa-containing HDC-ASCT. Case 1: A 56-year-old woman who relapsed 2 months after the first complete remission (CR) and underwent ASCT. Case 2: A 65-year-old woman who relapsed 8 months after the first CR and underwent ASCT. Both patients engrafted. Time to neutrophil engraftment was 10 and 12 days after HDC-ASCT, and CR was sustained for 26 and 18 months, respectively, as of the last follow-up. Although there is little evidence supporting the utility of thiotepa-based HDC-ASCT in patients with NL, the results of this case report suggest that further studies are warranted to determine its efficacy in this setting.</description><identifier>ISSN: 0925-5710</identifier><identifier>EISSN: 1865-3774</identifier><identifier>DOI: 10.1007/s12185-023-03544-8</identifier><identifier>PMID: 36689064</identifier><language>eng</language><publisher>Singapore: Springer Nature Singapore</publisher><subject>Autografts ; B-cell lymphoma ; Case Report ; Chemotherapy ; Hematology ; Leukocytes (neutrophilic) ; Lymphocytes B ; Lymphoma ; Medicine ; Medicine & Public Health ; Nervous system ; Oncology ; Peripheral nervous system ; Remission ; Stem cell transplantation ; Stem cells ; Transplantation</subject><ispartof>International journal of hematology, 2023-07, Vol.118 (1), p.141-145</ispartof><rights>Japanese Society of Hematology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. Japanese Society of Hematology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c350t-47c267412f7248af74766ccb03a07296c2b4e1db266c017437ccb9df1ba7b2673</cites><orcidid>0000-0001-8283-4997</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12185-023-03544-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12185-023-03544-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36689064$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Miyajima, Toru</creatorcontrib><creatorcontrib>Ogasawara, Reiki</creatorcontrib><creatorcontrib>Tsukamoto, Shihori</creatorcontrib><creatorcontrib>Ishio, Takashi</creatorcontrib><creatorcontrib>Yokoyama, Emi</creatorcontrib><creatorcontrib>Izumiyama, Koh</creatorcontrib><creatorcontrib>Mori, Akio</creatorcontrib><creatorcontrib>Saito, Makoto</creatorcontrib><creatorcontrib>Morioka, Masanobu</creatorcontrib><creatorcontrib>Kondo, Takeshi</creatorcontrib><title>Thiotepa-based high-dose chemotherapy with autologous stem cell transplantation for neurolymphomatosis</title><title>International journal of hematology</title><addtitle>Int J Hematol</addtitle><addtitle>Int J Hematol</addtitle><description>Neurolymphomatosis (NL) is a rare clinical entity characterized by lymphomatous infiltration of the peripheral nervous system. According to recent retrospective data, consolidative high-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) may be beneficial for NL. However, few reports to date have discussed optimal conditioning regimens. Herein, we report two cases of NL in patients with relapsed intravascular large B-cell lymphoma who received consolidative thiotepa-containing HDC-ASCT. Case 1: A 56-year-old woman who relapsed 2 months after the first complete remission (CR) and underwent ASCT. Case 2: A 65-year-old woman who relapsed 8 months after the first CR and underwent ASCT. Both patients engrafted. Time to neutrophil engraftment was 10 and 12 days after HDC-ASCT, and CR was sustained for 26 and 18 months, respectively, as of the last follow-up. Although there is little evidence supporting the utility of thiotepa-based HDC-ASCT in patients with NL, the results of this case report suggest that further studies are warranted to determine its efficacy in this setting.</description><subject>Autografts</subject><subject>B-cell lymphoma</subject><subject>Case Report</subject><subject>Chemotherapy</subject><subject>Hematology</subject><subject>Leukocytes (neutrophilic)</subject><subject>Lymphocytes B</subject><subject>Lymphoma</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Nervous system</subject><subject>Oncology</subject><subject>Peripheral nervous system</subject><subject>Remission</subject><subject>Stem cell transplantation</subject><subject>Stem cells</subject><subject>Transplantation</subject><issn>0925-5710</issn><issn>1865-3774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp9kU9L5TAUxYMo-kb9Ai4k4MZNNP-amy5FZpwBwY2uQ9qmr5W2qUmKvG9vnk9HcOEqcO_vnpx7D0JnjF4xSuE6Ms50QSgXhIpCSqL30IppVRABIPfRipa8IAUweoR-xfhMKQMq4RAdCaV0SZVcofax631ysyWVja7BXb_uSOOjw3XnRp86F-y8wa996rBdkh_82i8Rx-RGXLthwCnYKc6DnZJNvZ9w6wOe3BL8sBnnzo82-djHE3TQ2iG604_3GD39-f14-5fcP9z9u725J7UoaCISaq5AMt4Cl9q2IEGpuq6osBR4qWpeSceaiudqXkYKyM2yaVllIRdBHKPLne4c_MviYjJjH7c-7eSyb8NBac041yqjF9_QZ7-EKbszPB9HiBL4VpDvqDr4GINrzRz60YaNYdRsUzC7FExOwbynYHQeOv-QXqrRNf9HPs-eAbEDYm5Naxe-_v5B9g2v25Pg</recordid><startdate>20230701</startdate><enddate>20230701</enddate><creator>Miyajima, Toru</creator><creator>Ogasawara, Reiki</creator><creator>Tsukamoto, Shihori</creator><creator>Ishio, Takashi</creator><creator>Yokoyama, Emi</creator><creator>Izumiyama, Koh</creator><creator>Mori, Akio</creator><creator>Saito, Makoto</creator><creator>Morioka, Masanobu</creator><creator>Kondo, Takeshi</creator><general>Springer Nature Singapore</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8283-4997</orcidid></search><sort><creationdate>20230701</creationdate><title>Thiotepa-based high-dose chemotherapy with autologous stem cell transplantation for neurolymphomatosis</title><author>Miyajima, Toru ; Ogasawara, Reiki ; Tsukamoto, Shihori ; Ishio, Takashi ; Yokoyama, Emi ; Izumiyama, Koh ; Mori, Akio ; Saito, Makoto ; Morioka, Masanobu ; Kondo, Takeshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c350t-47c267412f7248af74766ccb03a07296c2b4e1db266c017437ccb9df1ba7b2673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Autografts</topic><topic>B-cell lymphoma</topic><topic>Case Report</topic><topic>Chemotherapy</topic><topic>Hematology</topic><topic>Leukocytes (neutrophilic)</topic><topic>Lymphocytes B</topic><topic>Lymphoma</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Nervous system</topic><topic>Oncology</topic><topic>Peripheral nervous system</topic><topic>Remission</topic><topic>Stem cell transplantation</topic><topic>Stem cells</topic><topic>Transplantation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miyajima, Toru</creatorcontrib><creatorcontrib>Ogasawara, Reiki</creatorcontrib><creatorcontrib>Tsukamoto, Shihori</creatorcontrib><creatorcontrib>Ishio, Takashi</creatorcontrib><creatorcontrib>Yokoyama, Emi</creatorcontrib><creatorcontrib>Izumiyama, Koh</creatorcontrib><creatorcontrib>Mori, Akio</creatorcontrib><creatorcontrib>Saito, Makoto</creatorcontrib><creatorcontrib>Morioka, Masanobu</creatorcontrib><creatorcontrib>Kondo, Takeshi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miyajima, Toru</au><au>Ogasawara, Reiki</au><au>Tsukamoto, Shihori</au><au>Ishio, Takashi</au><au>Yokoyama, Emi</au><au>Izumiyama, Koh</au><au>Mori, Akio</au><au>Saito, Makoto</au><au>Morioka, Masanobu</au><au>Kondo, Takeshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Thiotepa-based high-dose chemotherapy with autologous stem cell transplantation for neurolymphomatosis</atitle><jtitle>International journal of hematology</jtitle><stitle>Int J Hematol</stitle><addtitle>Int J Hematol</addtitle><date>2023-07-01</date><risdate>2023</risdate><volume>118</volume><issue>1</issue><spage>141</spage><epage>145</epage><pages>141-145</pages><issn>0925-5710</issn><eissn>1865-3774</eissn><abstract>Neurolymphomatosis (NL) is a rare clinical entity characterized by lymphomatous infiltration of the peripheral nervous system. According to recent retrospective data, consolidative high-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) may be beneficial for NL. However, few reports to date have discussed optimal conditioning regimens. Herein, we report two cases of NL in patients with relapsed intravascular large B-cell lymphoma who received consolidative thiotepa-containing HDC-ASCT. Case 1: A 56-year-old woman who relapsed 2 months after the first complete remission (CR) and underwent ASCT. Case 2: A 65-year-old woman who relapsed 8 months after the first CR and underwent ASCT. Both patients engrafted. Time to neutrophil engraftment was 10 and 12 days after HDC-ASCT, and CR was sustained for 26 and 18 months, respectively, as of the last follow-up. Although there is little evidence supporting the utility of thiotepa-based HDC-ASCT in patients with NL, the results of this case report suggest that further studies are warranted to determine its efficacy in this setting.</abstract><cop>Singapore</cop><pub>Springer Nature Singapore</pub><pmid>36689064</pmid><doi>10.1007/s12185-023-03544-8</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0001-8283-4997</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0925-5710 |
| ispartof | International journal of hematology, 2023-07, Vol.118 (1), p.141-145 |
| issn | 0925-5710 1865-3774 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2768812286 |
| source | Springer Nature - Complete Springer Journals |
| subjects | Autografts B-cell lymphoma Case Report Chemotherapy Hematology Leukocytes (neutrophilic) Lymphocytes B Lymphoma Medicine Medicine & Public Health Nervous system Oncology Peripheral nervous system Remission Stem cell transplantation Stem cells Transplantation |
| title | Thiotepa-based high-dose chemotherapy with autologous stem cell transplantation for neurolymphomatosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T14%3A26%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Thiotepa-based%20high-dose%20chemotherapy%20with%20autologous%20stem%20cell%20transplantation%20for%20neurolymphomatosis&rft.jtitle=International%20journal%20of%20hematology&rft.au=Miyajima,%20Toru&rft.date=2023-07-01&rft.volume=118&rft.issue=1&rft.spage=141&rft.epage=145&rft.pages=141-145&rft.issn=0925-5710&rft.eissn=1865-3774&rft_id=info:doi/10.1007/s12185-023-03544-8&rft_dat=%3Cproquest_cross%3E2768812286%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2890339727&rft_id=info:pmid/36689064&rfr_iscdi=true |